Piperaquine/dihydroartemisinin (DHA/PPQ), sold under the brand name Eurartesim among others, is a fixed dose combination medication used in the treatment of malaria. It is a combination of piperaquine and dihydroartemisinin. Specifically it is used for malaria of the P. falciparum and P. vivax types. It is taken by mouth.
|Trade names||DuoCotecxin, Artekin, Eurartesim, others|
|Other names||Dihydroartemisinin/piperaquine phosphate|
Side effects are uncommon. Concerns include the possibility of QT prolongation. Versions are available for use in children. Use in early pregnancy is not recommended. The two medications work by different mechanisms.
Piperaquine/dihydroartemisinin was approved for medical use in Europe in 2011. It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system. While it was available for about US$6 per treatment course, efforts are underway as of 2010 to bring the price down one dollar per course. It is commercially available in Africa and Asia. It has been used to treat more than 4.5 million people as of 2017.
Dihydroartemisinin (also known as dihydroqinghaosu, artenimol or DHA) is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate, artemether, etc.) and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs.
Piperaquine is an antimalarial drug, a bisquinoline first made in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. Usage declined in the 1980s as piperaquine-resistant strains of P. falciparum arose and artemisinin-based antimalarials became available. The combination dihydroartemisinin-piperaquine is an effective antimalarial that is used widely around the world. In South-East Asia, where resistance has emerged towards both artemisinin and piperaquine, the combination is being trialed with a third drug, namely mefloquine.
Piperaquine is characterized by slow absorption and a long biological half-life, making it a good partner drug with artemisinin derivatives which are fast acting but have a short biological half-life.
Society and cultureEdit
This product is available in the market of several countries:
- Artekin (Holleykin)
- Eurartesim (Sigma Tau; by Good Manufacturing Practices)
- Diphos (Genix Pharma)
- Timequin (SAMI Pharma )
- Duocotecxin (Holley Pharm)
- Malacur (Elder Pharmaceuticals for SALVAT Laboratories)
- Ridmal (Ajanta Pharma Limited)
- "Eurartesim 320 mg/40 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 10 April 2017. Retrieved 2 May 2020.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Eurartesim EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 3 May 2020.
- "Dihydroartemisinin/Piperaquine Application for Inclusion in the 17th WHO Model List of Essential Medicines" (PDF). WHO. November 2010. Retrieved 29 June 2017. CS1 maint: discouraged parameter (link)
- "TRAC II - Mahidol Oxford Tropical Medicine Research Unit". www.tropmedres.ac. Archived from the original on 28 July 2017. Retrieved 28 July 2017. CS1 maint: discouraged parameter (link)
- "Dihydroartemisinin mixture with piperaquine". Drug Information Portal. U.S. National Library of Medicine.
- "Dihydroartemisinin mixture with piperaquine tetraphosphate". Drug Information Portal. U.S. National Library of Medicine.